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Abstract:   
The 1950’s was a period of notable intellectual 
growth and collaboration. During that period new 
isotopic elements evolved to new treatments for 
cancer patients, both women and men.  The 
University of Iowa proved to be a fertile 
intellectual community where Gold 198 colloid 
successfully advanced survival for both ovarian 
and prostate cancer. 
Other collaboration expanded the fields of male 
and female infertility.  Both departments benefit 
from this early pioneering work to the present 
day. 
Iowa prostate cancer treatment prior 
to radioactive gold: 
The historical review paper of prostate 
cancer patients treated in the 1940’s, 
published by Dr. Rubin Flocks in 1950, 
demonstrated a life expectancy that was 
decidedly grim with 2.5-year average 
survival (Figure 1). Flocks’ best outcome 
data were obtained with transurethral 
resection and delayed estrogen 
treatment [4.5 years average survival].1 
Similar clinical confirmatory data from 
the University of Michigan reported by 
Dr. Reed Nesbit suggested limited 
survival among elderly prostate cancer 
patients.2  
 
Figure 1: Average survival of prostate 
cancer patients in the 1940’s with 
different treatments. 
Returning to University Hospitals from 
the Manhattan Project in Oak Ridge 
Tennessee (1946), Dr. William C. 
Keettel found useful therapy for ovarian 
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cancer with colloidal radioactive gold, 
Au198. The isotope had a relatively 
short half-life of 2.7 days. Its beta 
emissions made it ideal for short-term 
radiation exposure. From the 
gynecologic literature, it seems 
reasonable to assume that Dr. Keettel 
had medical peers at Oakridge who 
helped him obtain colloidal gold to treat 
his ovarian cancer patients. Thus, the 
isotope was available on the day his 
colleague Rubin Flocks needed a 
substitute for the radon seeds, which 
were being used to treat prostate cancer 
but were unavailable. 
Initial observations with radioactive 
gold and cancer of the prostate: 
When Dr. Flocks became Chairman of 
Urology (1949-50), he turned to the use 
of radioisotopes in the treatment of 
carcinoma of the prostate.3  At the end 
of World War II various radioisotopes 
became available for study, including 
Au198 that was used to treat ovarian 
cancer.4 On March 21, 1951, Dr. Flocks 
injected 60 millicuries of colloidal Au198 
into the prostate cancer of an 80 y/o 
patient with a large bulky prostate 
cancer that was refractory to estrogen 
therapy. The patient had been clinically 
evaluated in October 1950 at University 
Hospitals, which revealed a T-3 cancer 
with seminal vesical involvement.  
Radon seeds (the more traditional 
treatment at that time), which were to be 
used to reduce the tumor mass, were 
not available on the patient’s day of 
surgery but radioactive gold (Au198) 
was. Dr. Flocks made the clinical 
judgment that treatment was important 
for this elderly gentleman. 
Postoperatively, the patient and Dr. 
Flocks were gratified by the marked 
shrinkage of the prostatic cancer in 
response to radio-gold colloid. One-and-
a-half years later, the patient had no 
palpable prostate lesion and biopsy 
demonstrated no cancer.5  
Thus, the anecdotal clinical patient 
event led to a clinical series of prostate 
cancer patients. Retrospective vision 
reveals that medical literature citations 
of the seminal Sherman papers about 
gold colloid from Washington University 
in St. Louis were different for urology, 
compared to gynecology or radiology.6,7  
The first citation by Flocks, Kerr, Elkins, 
and Culp3referred to the same papers 
as “Allen, W. M., Bonebrake M. D. and 
Sherman, A. L. Abstracts of Roentgen 
Ray Society Meeting St. Louis Mo. 
1950”.  The citation suggests that Flocks 
knew about the presentation but 
probably did not have the paper directly 
available to him as he wrote his paper.  
Dr. Flocks’ narrative style demonstrated 
that he understood the potential benefits 
of the gold therapy. Sherman’s patient 
population demonstrated transport of 
the radio-gold to pelvic regional lymph 
nodes with sufficient fine distribution to 
destroy metastatic cancer to nodes. 
Initially, Flocks used primarily 
transperineal injection routes but also 
explored suprapubic, retropubic, 
transrectal, and transvesical injections 
to distribute the radioactive colloidal 
gold into the cancerous tissue. Dr. 
Flocks injected colloid gold into 552 
patients, varying his injections based on 
tumor shrinkage response. All these 
early patients (February 1951 to March 
1954) were treated by injection of the 
colloidal gold into the tumor without 
removal of prostatic tissue. Individual 
patients might have from one to seven 
injections of the radioactive agent at 
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variable time intervals. In 1959, Flocks 
reported on his outcomes with 730 
procedures performed in 517 patients 
treated with a range of 1-7 injections of 
colloidal gold per patient based on 
clinical response.8 
In Dr. Dabney Kerr’s view, the outcome 
for the injection patients suggested that 
a large population of cancer patients 
were not being treated. As such, Dr. 
Kerr had a major impact in Dr. Flocks’ 
decision to change the surgical pattern.  
 
Figure 2: Extended survival with 
radioactive gold: Flocks kept an 
elaborate catalogue of all 1515 
patients treated over the 25 years of 
his chairmanship. 
 
Contributions by Raymond George 
Bunge and James R. Bradbury 
During the Flocks Era, a number of 
long-term colleagues, research 
associates, and short term associates 
joined the clinical faculty, adding 
additional talent to the department. 
Clearly Dr. Bunge and Dr. Culp had long 
and distinguished careers at Iowa and 
their contributions are illustrated below 
Dr. Raymond George Bunge, 
Professor Urology: 1938-1998  
Dr. Bunge was one of those provocative 
characters who loved to stimulate new 
thought. He would ask the probing 
questions, like “how do you know that to 
be so?” —or —“on what basis do you 
make such a rash judgment?” He 
wanted the urology resident or student 
to think about the database—the source 
of knowledge on which a hypothesis 
was based. As Dr. (Sir) William Osler 
talked about “brain dusting”, Bunge 
wanted you to think about what you 
thought you knew and what you did not 
know in reality. He was clearly a person 
who thought “outside the box,” to borrow 
modern terminology. 
He loved the process of analysis—
finding a solution to a clinical problem. 
He didn’t always verbalize his thinking 
process but was willing to explore the 
possibilities, moving ever closer to the 
diagnosis and smiling with deep 
satisfaction when the appropriate 
diagnosis was made. Thus, he loved to 
explore his pet area of expertise: 
problems of intersex. He coined the 
term, believing that all the genetic, 
endocrinologic, phenotypic, and psychic 
factors had not been explored. While he 
was clearly aware of Greek mythology 
and its morphic descriptions, he felt that 
mythic descriptions were not the 
solution. His writings on intersex 
delineate his facile mind. 
Ray loved abstract art including that 
which he created himself. He, like 
Michelangelo, created images with 
sexual overtones. Buried in his work 
might be male genitalia within another 
image. 
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Figure 3: Ink and Water Print, Ray 
Bunge original 
Bunge’s first contributions to the 
urologic literature, upper tract cytology 
In 1950, shortly after returning from 
Army assignments in World War II, Dr. 
Bunge published three papers on renal 
upper tract cytology. The first case 
report represented an unusual 
intraparenchymal tumor that shed large 
bizarre multinucleated cells.8 This was 
quickly followed with a series of 11 
patients with renal cell cancer, all 
demonstrating abnormal cytology in 
retrograde renal pelvis urines. 
Papanicolaou staining demonstrated the 
multinucleated renal cells characteristic 
of the abnormal growth.9 By the fall of 
1950, Dr. Bunge had identified 
transitional cell cancer in ureteral 
specimens and had cultured the 
transitional cells.10 That same year, he 
wrote a paper on seven patients with 
various upper tract, ureteral, and 
bladder transitional cancers that 
demonstrated the place of urine 
cytology in diagnosis. He demonstrated 
that cellular atypia characteristics of the 
various tumors.11 Clearly, like Dr. Flocks, 
Dr. Bunge had an inquisitive mind and, 
through collaboration with his peers in 
Obstetrics and Gynecology, he brought 
new cytological staining techniques to 
bear on urologic disease. His interest in 
cytology continued with the use of 
triphenyltetrazolium chloride, violet. He 
found straining in normal renal tissue 
but not in renal cell cancer, epidermoid 
cancer or nephroblastoma tissue. 
Branching out slightly, Dr. Bunge 
identified and reported a patient with 
blastomycosis presenting as a prostate 
infection. Regardless, the examination 
represented culture and histologic 
examination of prostatic secretions.12 
Bunge’s collaboration with his resident, 
Dr. Bill Harness,13 led to another case 
report of an infantile multicystic kidney, 
a difficult diagnosis in the era before 
renal ultrasound. The excised surgical 
specimen proved the diagnosis 
originally thought to represent a 
nephroblastoma neoplasm. His 
extensive output for the medical 
literature was clearly recognized locally 
as Dr. Bunge was promoted to full 
Professor at Iowa in the 1952-3 
academic years.  
Bunge’s contributions to urology and 
male infertility 
Dr. Bunge’s most profound contributions 
to the medical literature were in the area 
of male infertility. In a series of 
experiments in the 1952-3 period he 
demonstrated viability in 60-70% of the 
cells from ejaculated sperm when the 
specimen was frozen slowly with dry ice 
and stored. When such specimens were 
subjected to freezing suspended in a 
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glycerol medium 1 part to 9 of sperm, 
they retained 50-70% viability of sperm 
cells. Moreover, he demonstrated that 
spermatozoa were unchanged in vital 
stain characteristics after this freezing 
process. Using this basic information, by 
October 1953, Bunge collaborated with 
Dr. William Keettel in Obstetrics and 
inseminated four women. Amazingly, he 
obtaining pregnancies and full term 
infants in all patients.14  
These observations “revolutionized” 
reproductive medicine. He originally 
submitted the paper to Science, and 
there was considerable “scientific” 
controversy between Dr. Bunge and 
editors for Science. It seemed that 
missed periods and positive pregnancy, 
Aschein-Zondek tests, were not 
sufficient to convince the scientific 
community of the time that these 
observations represented a normal 
pregnancy. One had to see a newborn 
baby to convince editors that women 
were really pregnant and carried the 
baby to term.15 In fact, Bunge had 
submitted the paper to Science in early 
July 1953 and had active 
correspondence with its editors who 
rejected the paper after deliberation. 
Bunge’s observations were ultimately 
published in Fertility and Sterility.14  
Ever a man of great humor, Dr. Bunge 
summarized his clinical work in a letter 
to his mother. Dr. Bunge wrote: “You tell 
uncle George that it won’t be long 
before my icicles [frozen sperm 
specimens] will be in the deep frozen 
section of the A&P stores [Atlantic and 
Pacific Tea Company] and that I 
probably will not continue to be a doctor 
but will just supply the huge demand for 
this material.”16 This one sentence 
suggested that male infertility had an 
immediate impact on the medical 
community and opened the door to 
artificial insemination for infertile 
couples. The subspecialty program in 
male infertility arose from these early 
clinical observations, in no small part 
related to Bunge’s work. The ethical 
issues generated by these scientific 
papers continue to divide society today 
but were not part of the discussion in 
these early clinical pilot studies. 
Keettel and Bunge provided follow up 
papers on pregnancy among infertile 
patients in 195413 and 1956.17 The 
reported pregnancies carried to term 
proved the effectiveness of the 
technique. Research reproductive 
physicians could now conceive of 
storing serial samples of patient’s 
semen to increase the number of sperm 
in infertile male patients. Sperm 
specimens were to be placed in an 
endo-cervical cap at ovulation to assure 
the most optimal circumstances for 
conception. 
In the late 1950’s Dr. Bunge and Dr. 
James Bradbury collaborated and 
reported on a child with a chromosomal 
abnormality of Klinefelter’s Syndrome 
and intra-tubular cells reminiscent of 
oocytes.18 A second paper in 1960 
demonstrated the progression of 
thought to incorporate the intersex 
states and the induction genital duct 
development towards either male or 
female lines.19 
These collaborative efforts advanced 
the subspecialties of male and female 
infertility and the stature of both 
departments in the medical world.  In 
Urology and Gynecology the fields of 
male and female infertility have 
dramatically expanded in the intervening 
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40+ years.  The study of intersex issues 
anatomic, endocrinological, and 
psychosocial development has 
expanded exponentially. 
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